Phage Display Competitive Binding Assay for SH2 Domain Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a highly sensitive and selective method to detect protein binders or protein binding partners for undruggable targets, as many proteins are not suitable for drug development due to their nature.
Innovation Solution
A competitive binding assay using phage display technology is employed to assess the binding affinity of test compounds with phage-displayed polypeptides, specifically SH2 domains, by immobilizing a reference ligand on a solid support and using qPCR amplification to determine the dissociation constant of the interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional phage display techniques are used to examine protein interactions, then the method is simple and well-established, but the sensitivity and selectivity are insufficient for detecting binders of undruggable targets
Solution Approach 1:
The assay is divided into distinct functional modules: (1) phage display library preparation with polypeptides of interest, (2) competitive binding reaction with immobilized reference ligand and test compound, (3) qPCR-based detection and quantification. This segmentation allows each module to be optimized independently while maintaining overall assay performance.
Solution Approach 2:
An immobilized reference ligand is introduced as an intermediary element that mediates the competitive binding reaction. The reference ligand, specific for the phage-displayed polypeptide, serves as a competitive inhibitor to enable indirect detection of test compound binding through displacement of phage from the immobilized ligand.
2Measurement precision
If competitive binding assay with immobilized reference ligand is used, then binding affinity can be accurately assessed, but the procedure becomes more complex compared to traditional phage display
Solution Approach 1:
The traditional mechanical/phage-counting-based detection method is replaced with qPCR amplification detection. By quantifying phage DNA through qPCR, the assay achieves higher precision in measuring binding affinity without relying on manual phage enumeration or complex mechanical separation steps.
Solution Approach 2:
The assay utilizes changes in binding parameters (dissociation constant Kd) as a function of test compound concentration. By measuring the concentration-dependent displacement of phage from the immobilized reference ligand, accurate binding affinity parameters can be derived through mathematical modeling of the competitive binding equilibrium.
3Measurement precision
If qPCR amplification is used to detect bound phage, then detection sensitivity is enhanced, but the required equipment and protocol complexity increase
Solution Approach 1:
The phage particles themselves serve a dual function: they display the polypeptide of interest for binding detection AND carry a DNA amplicon that serves as the template for qPCR amplification. This self-service approach eliminates the need for separate labeling or tagging steps, as the phage genome provides both the functional element and the detection signal.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a robust and reliable means to identify and quantify the binding affinity of test compounds to protein domains of interest, enabling the evaluation of undruggable targets as potential drug candidates and facilitating drug discovery.
Implementation Method 1
the reference ligand is specific for the phage-displayed polypeptide
Implementation Method 2
detecting the phage-displayed SH2 domain bound to the immobilized reference ligand via qPCR amplification of a DNA amplicon located within the phage genome
Data Source
AI summary
The present invention provides methods and kits for identifying interactions between a test compound and a phage-displayed polypeptide, wherein the phage-displayed polypeptide is not a kinase but a protein domain of interest, such as an SH2 domain of interest. The protein domain of interest is displayed on the phage, and the interactions are evaluated in the presence of a reference ligand and in the presence and absence of the test compound.